# Long-acting Injectable Risperidone in Patients With Schizophrenia After an Acute Episode

> **NCT00216671** · PHASE4 · COMPLETED · sponsor: **Janssen Pharmaceutica N.V., Belgium** · enrollment: 220 (actual)

## Conditions studied

- Schizophrenia

## Interventions

- **DRUG:** early initiation of treatment with Risperdal Consta
- **DRUG:** routine initiation of treatment with Risperdal Consta

## Key facts

- **NCT ID:** NCT00216671
- **Lead sponsor:** Janssen Pharmaceutica N.V., Belgium
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE4
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2005-11
- **Primary completion:** 2009-12
- **Final completion:** 2009-12
- **Target enrollment:** 220 (ACTUAL)
- **Last updated:** 2013-07-19


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT00216671

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT00216671, "Long-acting Injectable Risperidone in Patients With Schizophrenia After an Acute Episode". Retrieved via AI Analytics 2026-06-12 from https://api.ai-analytics.org/clinical/NCT00216671. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*